2013 DSEN Meetings
This 5th semi-annual meeting, held by DSEN on October 18th, 2013 at Albert at Bay Suite Hotel, was attended by 46 participants from the research and the decision making arenas.
The principal objectives of this meeting were:
- To understand the functioning of provincial and territorial drug plans and decision-making processes
- To engage Network members in discussion on the specific information needs of provinces and territories
- To provide network-wide interactions between DSEN funded researchers and decision makers
Robert Peterson, the DSEN Executive Director gave welcoming remarks and explained that the objectives of the meeting revolved around what happens in the provinces after a drug is authorized for release on the Canadian market. CADTH’s Director of the Common Drug Review (CDR) and Optimal Use of Drugs, Chander Seghal, presented the CDR and other services offered to the provinces and territories by CADTH. Carole Marcotte, Director of drug evaluation for listing at the Institut d’excellence en santé et services sociaux (INESSS) in Québec explained the functioning of the institute and the integrated decision making in the province. Diane Forbes from the DSEN CO presented the key points and the rationale for the joint project developed between DSEN and CADTH, which aims to support the submission of Queries relevant to decision making within public drug plans. Lunch was accompanied by a keynote presentation by Brian O’Rourke, President and Chief Executive Officer of CADTH, who spoke to synergies and opportunities in CADTH and DSEN collaborating.
The afternoon session was devoted to the work accomplishments by the network teams and collaborating centres addressing Queries submitted by provinces and territories.
The Drug Safety and Effectiveness Network (DSEN) held its fourth semi-annual Network meeting on March 22nd, 2013 at Health Canada’s premises in Ottawa. This meeting was attended by 48 participants from the research and the decision making arenas.
The main objectives of this 4th semi-annual meeting were:
- to engage Network members in discussion on the specific information needs of drug regulatory agencies;
- to provide network-wide interactions between DSEN funded researchers and decision makers;
- to update participants on recent developments and upcoming plans and activities; and
- to support a culture of knowledge translation (KT) within the DSEN program.
The morning session was devoted to DSEN funded investigators to report on a single Query and provide updates on specific projects relevant to the decision makers present amongst the audience. Lunch time was allocated to keynote presentations by Gerald Dal Pan, Senior Official from the U.S. Food and Drug Administration (FDA) to share international insight and by Health Canada Senior Management staff Anne Lamar and Cindy Evans.
In the afternoon, Diane Forbes, DSEN Associate Director presented a summary of the KT workshop held in early March 2013 for DSEN investigators on results reporting. Thereafter, four representatives from HPFB gave Health Canada’s perspective of the program, explained their expectations from the DSEN researchers and expressed their openness to further collaborate with DSEN investigators to better serve the Query submission process. A panel discussion took place later in the afternoon and it was an opportunity to integrate expectations and research capacity in the discussion so researchers and decision makers have a better and clearer understanding of different steps of the process. Finally, DSEN Executive Director announced upcoming events where DSEN will be actively engaged and gave an update on funding opportunities. A tentative date for the next semi-annual network meeting was given before the meeting was adjourned.
- Date modified: